CANCER EDUCATION GRANT PROGRAM RELEASE DATE: April 3, 2003 PA NUMBER: PAR-03-093 (This PA has been reissued, see PAR-05-065) (This Program Announcement (PAR) replaces PAR-00-033, which was published in the NIH Guide on December 22, 1999.) EXPIRATION DATE: February 2, 2005 National Cancer Institute (NCI) (http://www.nci.nih.gov/) CATALOG OF FEDERAL DOMESTIC ASSISTANCE NUMBER (S): 93.398 THIS PAR CONTAINS THE FOLLOWING INFORMATION o Purpose of the PAR o Objectives of the Cancer Education Grant Program o Mechanism of Support o Eligible Institutions o Individuals Eligible to Become Principal Investigators o Special Requirements o Where to Send Inquiries o Submitting an Application o Peer Review Process o Review Criteria o Award Criteria o Required Federal Citations PURPOSE The purpose of the Cancer Education Grant Program (CEGP) is to support the development and dissemination of innovative education approaches, methods and tools that ultimately will have an impact on reducing cancer incidence, mortality, morbidity, and improving the quality of life of cancer survivors. OBJECTIVES OF THE CANCER EDUCATION GRANT PROGRAM Background: The Cancer Education Grant Program, which employs the R25 grant mechanism, was reorganized in 1993 to provide institutions a wide range of opportunities to develop and sustain unique, innovative, primarily curriculum-driven programs that focus on various cancer education activities as opposed to the conduct of biomedical research. The development of more refined, more effective education methods and tools for biomedical scientists, health care professionals, students and the lay community are essential components of the overall mission of the National Cancer Institute to reduce cancer incidence and mortality. Unlike typical research grants, which test research outcomes using experimental controls, R25 grants are experiments in new educational approaches that determine their success or failure through the application of carefully designed evaluation plans. Objectives: The Cancer Education Grant Program of the National Cancer Institute is a flexible, primarily curriculum-driven program aimed at developing and sustaining innovative educational approaches that ultimately will have an impact on reducing cancer incidence, morbidity, mortality, and on improving the quality of life of cancer survivors. The CEGP invites investigator-initiated R25 grant applications that pursue a wide range of objectives from short courses, national forums, seminars, and/or hands-on workshops designed to educate scientists, health care professionals, students and the lay community; to the design, development and evaluation of new curricula of special significance to cancer in educational institutions; structured short-term didactic and research experiences designed to motivate high school, college and medical, dental and other health professional students to pursue careers in cancer research; to the development and evaluation of new educational methods and tools directed at special audiences (e.g., minorities and underserved populations); to web-based and virtual approaches to cancer education. The ranges of possibilities for this award are unlimited; as long as they focus on new approaches to cancer education, can be disseminated effectively, and potentially have wide applicability. Because of the wide spectrum of possible ways to use the Cancer Education Program, all applicants are urged to contact NCI program staff before preparing an application (see WHERE TO SEND INQUIRIES) MECHANISM OF SUPPORT The NCI Cancer Education Grant Program uses the NIH R25 grant mechanism. As an applicant, you will be solely responsible for planning, directing, and executing the proposed project. New applicants may request up to five years of support in a single grant period in order to develop or maintain a specific education program. The maximum support in direct costs per year is $300,000. Applications exceeding this cap will be returned unless specific permission has been obtained in writing from the NCI program staff. Facilities and administration (F & A) costs, which formerly were called indirect costs, will be reimbursed at 8 percent of the modified direct costs. It is important to note that subcontracts are also restricted to the same 8% reimbursement of modified direct costs. For purposes of determining the cap, indirect costs included in a subcontract will not count against the direct cost cap. Independently from the amount requested, this PAR does not use a modular budget. A complete and detailed budget should be submitted. This PAR is not subject to "Just-in-time" application procedures or to the Streamlined Non- competing Application Process (SNAP). The R25 remains under "Expanded Authorities" except that carryover of funds from one fiscal year to the next requires approval by the NCI. In general, allowable costs must be consistent with NIH policy and the recommendations of peer reviewers. These costs include but are not limited to the following: personnel costs, supplies, student compensation (when appropriate), student subsistence allowance (e.g., partial costs for meals and/or for lodging, when appropriate), other student costs (e.g., tuitions, travel expenses, when appropriate), consultant costs, equipment, travel, subcontractual costs (as long as subcontracts are not awarded with a higher indirect cost than 8%), and other expenses. It is recommended that potential applicants consult NCI staff if there are any questions regarding allowable costs. Because the CEGP is primarily intended to support studies that can be completed within five years and sustained afterwards with other resources (e.g., institutional, community), all applications submitted as competing renewals must receive prior consultation and written approval from NCI program staff. Programs with reasonable justification, such as short-term cancer research and educational experiences designed to motivate individuals to pursue cancer research careers (e.g., medical students) or educational programs for disadvantaged, underserved and minority populations that experience higher cancer incidence and mortality, are generally approved for submission. ELIGIBLE INSTITUTIONS o Domestic (See below for exceptions) o For Profit or non-profit organizations and professional societies o Public or private institutions, such as universities, colleges, hospitals, and laboratories o Units of State and local governments o Eligible agencies of the Federal government o Faith-based or community-based organizations Eligibility to apply for a grant is normally limited to domestic institutions. Under special circumstances foreign institutions may request a formal waiver of this requirement after consulting with and receiving written approval from NCI. INDIVIDUALS ELIGIBLE TO BECOME PRINCIPAL INVESTIGATORS The Program Leader/Principal Investigator must be an expert educator/investigator in the proposed field and be able to provide both administrative and scientific leadership to the Program. Racial/ethnic minority individuals, women, and persons with disabilities are encouraged to apply as principal investigators. SPECIAL REQUIREMENTS R25 grant applications submitted under this announcement may not be used to conduct traditional research or training. The NCI requires that R25 grant applications submitted in response to this announcement contain two special sections: (1) an "Evaluation Plan" that clearly denotes how the proposed education program will be evaluated for success or failure based on its purpose and objectives. One of the evaluation criteria should focus on the degree of applicability the proposed program will have to other educational institutions, geographic areas and/or different populations; and (2) a "Dissemination Plan" that clearly indicates how the applicant will communicate and make available the results of the study (e.g., publications, presentations) to the potential user community (e.g., cancer centers, universities and other educational institutions, professional societies, communities etc.). Applications submitted without these two sections will not receive further consideration. When the application is designed for completion within a five year period or less using Federal resources AND is expected to continue without additional Federal support, the applicant institution must include a plan, with appropriate commitment of resources, to continue the effort after the period of grant support ends. Examples of these kinds of studies might be curriculum development within the institution in areas of critical importance to cancer education (e.g., nutrition, pain management) or efforts directed to the community (e.g., outreach programs to the lay public, educational programs for community health care professionals). A final progress report, invention statement, and Financial Status Report are required upon termination of an award. Evaluation from NCI: In carrying out its stewardship of human resource related programs, the NCI may request information essential to an assessment of the effectiveness of this program. Accordingly, recipients are hereby notified, that they may be contacted after the completion of this award for periodic updates on various aspects of the educational program including, but not limited to, achievement obtained through the program, trainee accomplishments, publications, dissemination, honors and awards, professional activities, and other information helpful in evaluating the impact of the program. WHERE TO SEND INQUIRIES We encourage your inquiries concerning this PAR and welcome the opportunity to answer questions from potential applicants. Inquiries may fall into three areas: scientific/research, peer review, and financial or grants management issues: o Direct your questions about scientific/research issues to: Dr. Maria Agelli National Cancer Institute Cancer Training Branch 6116 Executive Boulevard, Suite 700 Bethesda, MD 20892 Telephone: (301) 496-8580 Email: ma215e@nih.gov o Direct your questions about peer review issues to: Referral Officer National Cancer Institute Division of Extramural Activities 6116 Executive Boulevard, Room 8041, MSC 8329 Bethesda, MD 20892-8329 Telephone: (301) 496-3428 FAX: (301) 402-0275 Email: ncirefof@dea.nci.nih.gov o Direct your questions about financial or grants management matters to: Ms. Catherine Blount National Cancer Institute Grants Administration Branch 6120 Executive Blvd. Room EPS 243 Bethesda, MD 20892 Phone: (301) 496-3179 Fax: (301) 496-8601 e-mail: blountc@mail.nih.gov SUBMITTING AN APPLICATION Applications should be prepared using the PHS 398 research grant application instructions and forms (rev. 5/2001). The CEGP allows for a wide range of approaches and topics but applicants are expected to generally follow the instructions and Table of Contents provided in the PHS 398-application kit with respect to the organization of the application. The PHS 398 is available at http://grants.nih.gov/grants/funding/phs398/phs398.html in an interactive format. For further assistance contact GrantsInfo, Telephone (301) 710-0267, Email: GrantsInfo@nih.gov. The instructions in the Form PHS 398 do not fully apply to the special needs of this grant application. Therefore, please follow the modified instructions below in preparing an application for an NCI Cancer Education Grant (R25) Program. These instructions have been adapted to accommodate the Form PHS 398 and the special needs of the CEGP: 1. Face Page: Use Form Page 1 of the Form PHS 398. On Line 1, include the title that best represents the nature of the training program. On Line 2, provide the number of this Program Announcement beginning with PAR-03-093, and the title "Cancer Education Grant Program (R25)". 2. Description/ Performance site(s)/ Key personnel (Form Page 2 of Form PHS 398): Under Performance Sites include "Consortium/ Contractual Arrangements" with a description of plans for collaborating with other institutions for the purpose of exchange and sharing of resources including faculty, equipment and facilities. If multiple sites are to be used, the applicant institution must be one of those sites and a strong justification must be provided for inclusion of the other sites in the proposed education program. 3. Resources: Use the Resource Format page and describe the educational environment. Include in this description the facilities, laboratories, participating departments, and any other resources to be used in the conduct of the proposed program. Use continuation pages as necessary. 4. Research Plan o Retitle Part C. "Preliminary Activities" and include if applicable. This section should contain information on the steps that have led to the proposed program. o Retitle Part D of this section "Cancer Education Program Plan". The information provided in this section should be organized as follows: a. Program Direction. Describe the qualifications and role of the PI to provide scientific and administrative leadership and coordination of the Program and the plans for management of the program. b. Program Faculty/ Staff. Describe the experience and responsibilities of the faculty and staff. c. Proposed Cancer Education Program. Briefly describe the background, purpose and objectives of the Program. Provide programmatic detail on special activities proposed (e.g., courses, curricula, workshops, etc.) as well as evidence of institutional and community commitment and support of the proposed program. Where appropriate, provide information on the proposed participants, and the plans for recruiting and retaining participants, including individuals from underrepresented racial/ethnic groups, women and persons with disabilities. d. Cancer Education Evaluation Plan. Provide a plan for evaluating the success of the program in achieving its goals and objectives. Applications that do not have an adequate evaluation plan will be considered non- responsive to this program announcement. e. Dissemination Plan. Provide a plan for disseminating the knowledge acquired from the education program. The plan should include a description of the venues that will be used and the populations, institutions, organizations, etc., that will be targeted for receiving information about the program. Applications that do not have an adequate dissemination plan will be considered non-responsive to this program announcement. f. Statement of Institutional Commitment. Where appropriate, evidence of institutional commitment and plans to continue funding the educational program after the period of grant support ends. 5. Human Subjects. The revised policy for IRB review of human subjects protocols in grant applications can be found at the following URL: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-031.html APPLICATION RECEIPT DATES: Applications submitted in response to this program announcement will be accepted at the standard application deadlines, which are available at http://grants.nih.gov/grants/dates.htm. Application deadlines are also indicated in the PHS 398 application kit. SENDING AN APPLICATION TO THE NIH: Submit a signed, typewritten original of the application, including the checklist, and three signed photocopies in one package to: Center for Scientific Review National Institutes of Health 6701 Rockledge Drive, Room 1040, MSC 7710 Bethesda, MD 20892-7710 Bethesda, MD 20817 (for express/courier service) To expedite the review process, which will be conducted by the NCI, two additional copies must be sent to: Referral Officer Division of Extramural Activities National Cancer Institute 6116 Executive Boulevard, Room 8041, MSC 8329 Bethesda, MD 20892-8329 Rockville, MD 20852 (for express/courier service) APPLICATIONS HAND-DELIVERED BY INDIVIDUALS TO THE NATIONAL CANCER INSTITUTE WILL NO LONGER BE ACCEPTED. This policy does not apply to courier deliveries (i.e. FEDEX, UPS, DHL, etc.) (http://grants.nih.gov/grants/guide/notice-files/ NOT-CA-02-002.html) This change in practice is effective immediately. This policy is similar to and consistent with the policy for applications addressed to Centers for Scientific Review as published in the NIH Guide Notice http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-012.html. APPLICATION PROCESSING: Applications must be received by the date(s) listed on the first page of this PAR. The CSR will not accept any application in response to this PAR that is essentially the same as one currently pending initial review unless the applicant withdraws the pending application. The CSR will not accept any application that is essentially the same as one already reviewed. This does not preclude the submission of a substantial revision of an application already reviewed, but such application must include an Introduction addressing the previous critique Although there is no immediate acknowledgement of the receipt of an application, applicants are generally notified of the review and funding assignment within 8 weeks. PEER REVIEW PROCESS Upon receipt, applications will be reviewed for completeness by the CSR and for adherence to the guidelines of this PAR by the NCI program staff. Applications not adhering to the guidelines of this PAR, and those applications that are incomplete as determined by CSR or by NCI program staff, will not receive further consideration. Applications that are complete and adhere to the guidelines of this PAR will be evaluated for scientific and technical merit by an appropriate peer review group convened by the Division of Extramural Activities of the NCI in accordance with the review criteria stated below. As part of the initial merit review, all applications will: o Receive a written critique o Undergo a process in which only those applications deemed to have the highest scientific merit, generally the top half of the applications under review, will be discussed and assigned a priority score o Those that receive a priority score will undergo a second level review by the National Cancer Advisory Board. REVIEW CRITERIA The goals of NIH-supported research are to advance our understanding of biological systems, improve the control of disease, and enhance health. In the written comments, reviewers will be asked to discuss the following aspects of your application in order to judge the likelihood that the proposed research will have a substantial impact on the pursuit of these goals: 1. Novelty and significance of the education program to cancer research and/or to the reduction of cancer incidence, morbidity, and mortality and to the improvement of quality of life of cancer survivors. 2. Quality of the program leader (principal investigator) in terms of past track record of achievement and experience to provide direction, coordination, and administration of the Program. 3. Quality of the key personnel and/or faculty who will participate in the Program. 4. The overall quality and adequacy of the design of the Program to achieve its short-term and long-term objectives. 5. Where appropriate, adequacy of plans for recruitment and retention of program participants, including participants from underrepresented racial/ethnic groups, women and persons with disabilities. 6. Degree of applicability and portability of the proposed program to other institutions, geographic areas, and populations. 7. Adequacy of the required "Evaluation Plan" to assess the effectiveness of the Program in achieving its objectives. 8. Adequacy of the "Dissemination Plan" to communicate and make available the results of the study through publications in professional journals, publications/presentations at national and international meetings, and internet websites; and to reach the potential user community effectively (e.g., cancer centers, universities and other educational institutions, professional societies, hospitals, other educators). 9. When the program is expected to continue without additional Federal Resources, sufficiency of the applicant institution's plan and commitment of resources to continue the Program after the period of Federal grant support ends. 10. The following review criteria apply only to proposed education programs that involve short-term experiences in a research environment and which are renewable: a. Quality of the proposed short-term education program, taking into account the quality (and track records, if a renewal application) of the program design, and of the educational environment; the commitment of the participating faculty; the availability of research support, inclusion of information related to new, rapidly developing topics/fields in biomedical research. b. Access to candidates for short-term experiences and the ability to recruit high quality individuals from the applicant institution or other schools. Evaluate the track record for a renewal application. c. Characteristics of the educational program that might be expected to persuade short-term participants to consider cancer research careers. Evaluate the track record for a renewal application. d. Success in attracting students back for repeated short-term appointments. e. Success in recruiting under-represented minorities. f. Plan to follow former participants and to assess the effect of such a program on their research careers. Evaluate the track record for a renewal application. 11. For all other renewal applications, the track record of productivity. ADDITIONAL REVIEW CRITERIA: In addition to the above criteria, the initial review group will also evaluate: PROTECTION OF HUMAN SUBJECTS FROM RESEARCH RISK: The involvement of human subjects and protections from research risk relating to their participation in the proposed research will be assessed. (See criteria included in the section on Federal Citations, below). INCLUSION OF WOMEN, MINORITIES AND CHILDREN IN RESEARCH: The adequacy of plans to include subjects from both genders, all racial and ethnic groups (and subgroups), and children as appropriate for the scientific goals of the research will be assessed. Plans for the recruitment and retention of subjects will also be evaluated. (See Inclusion Criteria in the sections on Federal Citations, below). CARE AND USE OF VERTEBRATE ANIMALS IN RESEARCH: If vertebrate animals are to be used in the project, the five items described under Section f of the PHS 398 research grant application instructions (rev. 5/2001) will be assessed. ADDITIONAL CONSIDERATIONS BUDGET: Appropriateness of the budget and duration of the support needed to achieve the stated goals and objectives. AWARD CRITERIA Applications submitted in response to a PAR will compete for available funds with all other recommended applications. The following will be considered in making funding decisions: o Educational merit of the proposed project as determined by peer review o Availability of funds o Relevance to program priorities REQUIRED FEDERAL CITATIONS HUMAN SUBJECTS PROTECTION: Federal regulations (45CFR46) require that applications and proposals involving human subjects must be evaluated with reference to the risks to the subjects, the adequacy of protection against these risks, the potential benefits of the research to the subjects and others, and the importance of the knowledge gained or to be gained. INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH: It is the policy of the NIH that women and members of minority groups and their sub-populations must be included in all NIH-supported clinical research projects unless a clear and compelling justification is provided indicating that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43). All investigators proposing clinical research should read the AMENDMENT "NIH Guidelines for Inclusion of Women and Minorities as Subjects in Clinical Research - Amended, October, 2001," published in the NIH Guide for Grants and Contracts on October 9, 2001 (http://grants.nih.gov/grants/guide/notice-files/ NOT-OD-02-001.html); a complete copy of the updated Guidelines are available at http://grants.nih.gov/grants/funding/women_min/guidelines_ amended_10_2001.htm.The amended policy incorporates: the use of an NIH definition of clinical research; updated racial and ethnic categories in compliance with the new OMB standards; clarification of language governing NIH-defined Phase III clinical trials consistent with the new PHS Form 398; and updated roles and responsibilities of NIH staff and the extramural community. The policy continues to require for all NIH-defined Phase III clinical trials that: a) all applications or proposals and/or protocols must provide a description of plans to conduct analyses, as appropriate, to address differences by sex/gender and/or racial/ethnic groups, including subgroups if applicable; and b) investigators must report annual accrual and progress in conducting analyses, as appropriate, by sex/gender and/or racial/ethnic group differences. INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS: The NIH maintains a policy that children (i.e., individuals under the age of 21) must be included in all human subjects research, conducted or supported by the NIH, unless there are scientific and ethical reasons not to include them. This policy applies to all initial (Type 1) applications submitted for receipt dates after October 1, 1998. All investigators proposing research involving human subjects should read the "NIH Policy and Guidelines" on the inclusion of children as participants in research involving human subjects that is available at http://grants.nih.gov/grants/funding/children/children.htm. REQUIRED EDUCATION ON THE PROTECTION OF HUMAN SUBJECT PARTICIPANTS: NIH policy requires education on the protection of human subject participants for all investigators submitting NIH proposals for research involving human subjects. You will find this policy announcement in the NIH Guide for Grants and Contracts Announcement, dated June 5, 2000, at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html. A continuing education program in the protection of human participants in research in now available online at: http://cme.nci.nih.gov/. HUMAN EMBRYONIC STEM CELLS (hESC): Criteria for federal funding of research on hESCs can be found at http://grants.nih.gov/grants/stem_cells.htm and at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-005.html. Guidance for investigators and institutional review boards regarding research involving human embryonic stem cells, germ cells, and stem cell-derived test articles can be found at http://grants.nih.gov/grants/guide/notice-files/ NOT-OD-02-044.html. Only research using hESC lines that are registered in the NIH Human Embryonic Stem Cell Registry will be eligible for Federal funding (see http://escr.nih.gov). It is the responsibility of the applicant to provide the official NIH identifier(s)for the hESC line(s) to be used in the proposed research. Applications that do not provide this information will be returned without review. PUBLIC ACCESS TO RESEARCH DATA THROUGH THE FREEDOM OF INFORMATION ACT: The Office of Management and Budget (OMB) Circular A-110 has been revised to provide public access to research data through the Freedom of Information Act (FOIA) under some circumstances. Data that are (1) first produced in a project that is supported in whole or in part with Federal funds and (2) cited publicly and officially by a Federal agency in support of an action that has the force and effect of law (i.e., a regulation) may be accessed through FOIA. It is important for applicants to understand the basic scope of this amendment. NIH has provided guidance at http://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm. Applicants may wish to place data collected under this PAR in a public archive, which can provide protections for the data and manage the distribution for an indefinite period of time. If so, the application should include a description of the archiving plan in the study design and include information about this in the budget justification section of the application. In addition, applicants should think about how to structure informed consent statements and other human subjects procedures given the potential for wider use of data collected under this award. STANDARDS FOR PRIVACY OF INDIVIDUALLY IDENTIFIABLE HEALTH INFORMATION: The Department of Health and Human Services (DHHS) issued final modification to the "Standards for Privacy of Individually Identifiable Health Information", the "Privacy Rule," on August 14, 2002. The Privacy Rule is a federal regulation under the Health Insurance Portability and Accountability Act (HIPAA) of 1996 that governs the protection of individually identifiable health information, and is administered and enforced by the DHHS Office for Civil Rights (OCR). Those who must comply with the Privacy Rule (classified under the Rule as "covered entities") must do so by April 14, 2003 (with the exception of small health plans which have an extra year to comply). Decisions about applicability and implementation of the Privacy Rule reside with the researcher and his/her institution. The OCR website (http://www.hhs.gov/ocr/) provides information on the Privacy Rule, including a complete Regulation Text and a set of decision tools on "Am I a covered entity?" Information on the impact of the HIPAA Privacy Rule on NIH processes involving the review, funding, and progress monitoring of grants, cooperative agreements, and research contracts can be found at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-025.html. URLs IN NIH GRANT APPLICATIONS OR APPENDICES: All applications and proposals for NIH funding must be self-contained within specified page limitations. Unless otherwise specified in an NIH solicitation, Internet addresses (URLs) should not be used to provide information necessary to the review because reviewers are under no obligation to view the Internet sites. Furthermore, we caution reviewers that their anonymity may be compromised when they directly access an Internet site. HEALTHY PEOPLE 2010: The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2010," a PHS-led national activity for setting priority areas. This PAR, Cancer Education Grant Program, is related to the priority area of cancer education and community based programs. Potential applicants may obtain a copy of "Healthy People 2010" at http://www.health.gov/healthypeople/. AUTHORITY AND REGULATIONS: This program is described in the Catalog of Federal Domestic Assistance No. 93.398 at http://www.cfda.gov/, and is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. Awards are made under authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and administered under NIH grants policies described at http://grants.nih.gov/grants/policy/policy.htm and under Federal Regulations 42 CFR 52 and 45 CFR Parts 74 and 92. The PHS strongly encourages all grant recipients to provide a smoke-free workplace and discourage the use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care, or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people.


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices



NIH Office of Extramural Research Logo
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy
NIH... Turning Discovery Into Health®



Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.